SCHEMBL25831517

SCHEMBL25831517

CCC(C)CCCCCOCCOCCCCCNC(=O)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ EPHX2 P34913 8/20 0.40
▸ GNAI3 P08754 1/20 0.38
▸ GNAO1 P09471 1/20 0.38
▸ GNAI1 P63096 1/20 0.38
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ RRM1 P23921 1/20 0.37
▸ GLP1R P43220 3/20 0.36
▸ DPP7 Q9UHL4 1/20 0.36
▸ TLR2 O60603 1/20 0.36
▸ ALDH1A2 O94788 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ ALDH2 P05091 1/20 0.36
▸ ALDH1A3 P47895 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25971939 0.90 DPP7 (0.45) KMT2AMEN1EPHX2GNAI3GNAO1
SCHEMBL23442922 0.89 GNAI3 (0.45) KMT2AMEN1GNAI3GNAO1GNAI1
SCHEMBL23806922 0.88 EPHX2 (0.46) KMT2AMEN1EPHX2GNAI3GNAO1
SCHEMBL21107012 0.86 KMT2A (0.46) KMT2AMEN1EPHX2GNAI3GNAO1
SCHEMBL23945209 0.85 KMT2A (0.42) KMT2AMEN1EPHX2GNAI3GNAO1
SCHEMBL22794783 0.84 MMP8 (0.49) KMT2AMEN1RRM1DPP7
SCHEMBL21107013 0.84 MMP8 (0.49) KMT2AMEN1RRM1DPP7
SCHEMBL23806827 0.84 GNAI3 (0.47) KMT2AMEN1EPHX2GNAI3GNAO1
SCHEMBL25654212 0.84 KMT2A (0.44) KMT2AMEN1EPHX2GNAI3GNAO1
SCHEMBL21105998 0.83 KMT2A (0.44) KMT2AMEN1EPHX2GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885EPHX2 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback